よむ、つかう、まなぶ。

MC plus(エムシープラス)は、診療報酬・介護報酬改定関連のニュース、

資料、研修などをパッケージした総合メディアです。


参考資料4_Action plan for whole genome analysis 2022 (15 ページ)

公開元URL https://www.mhlw.go.jp/stf/newpage_35569.html
出典情報 厚生科学審議会 科学技術部会全ゲノム解析等の推進に関する専門委員会(第17回 10/3)《厚生労働省》
低解像度画像をダウンロード

資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。

Figure 4. Basic Strategies of the Action Plan for Whole Genome Analysis
Basic Strategies of the Action Plan for Whole Genome Analysis
The present project has determined the basic strategies shown below, and with the aim of
overcoming cancer and rare/intractable diseases, practical application will start in fields
where the results of whole genome analysis are obtained.
1) Basic strategies for use in research and drug discovery
• To ensure comprehensive return to patients of the results of whole genome analysis, it is
important to stimulate research and drug discovery using the accumulated genome data.
Initiatives in collaboration with the Industry Consortium and the Academic Consortium will
therefore be promoted, with the aim of nurturing industries through the creation of
innovation originating in Japan, while at the same time new treatments will be made
available to patients.
• A system will be put in place to allow open and fair use of the accumulated whole genome
analysis information by researchers in domestic and foreign research institutions and
companies.
2) Basic strategy for early introduction of results into clinical practice
• Where the results of whole genome analysis give a certain degree of evidence for
technologies to select appropriate treatment methods or diagnose diseases, the goal will
be for these to be covered by national health insurance in the future.
3) Basic strategy for achieving new, personalized medical care
• New clinical studies and trials will be conducted, in addition to which real-world evidence
will be compiled, to achieve more personalized medical care through advanced, efficient
diagnosis and treatment.

14